

MODERN MOBILITY AIDS, INC.

(FORMERLY GALILEO LIFE SCIENCES, INC.)

1968 S. Coast Hwy. Suite1094, Laguna Beach CA 92651

Phone: 416 254 2581, email: tdimarco@mdrminc.com

QUARTERLY REPORT

For the Quarter Ended September 30, 2024

(the "Reporting Period")

As of September 30, 2024, the number of shares outstanding of our Common Stock was: 305,012,448

As of June 30, 2024, the number of shares outstanding of our Common Stock was: 305,012,448

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

1. Name and addresses (es) of the issuer and its predecessor (if any)

Modern Mobility Aids Inc, (the "Company", "we", "us", or "our") was incorporated under the laws of the State of Nevada on December 19, 2007 ("Inception") under the name Glider Inc. with a business plan to sell and distribute products for mobility challenged individuals. The Company changed its name to Modern Mobility Aids, Inc. on April 22, 2010, and to Galileo Life Sciences, Inc. on December 12, 2014. Effective October 3, 2017, the Board of Directors, pursuant to unanimous written consent of the board, authorized a change in the Company's name back to Modern Mobility Aids, Inc. On the same day, the Company filed a Certificate of Amendment with the Nevada Secretary of State amending its articles of incorporation to reflect the change in corporate name to "Modern Mobility Aids Inc.". The Company's current status with the state of Nevada is active. The Company changed its name to Galileo Life Sciences, Inc. on March 12, 2021, and then again changed its name back to Modern Mobility Aids Inc. on November 19, 2023. The Company's website is www.modernmobilityaids.com.

The Company has incorporated four wholly owned subsidiary companies: Modern Mobility Aid Inc., (name changed to Ayden Health Inc. on May 22, 2020), an Ontario, Canada, based company registered on September 09, 2009, and MDRM Group (Canada) Ltd. an Ontario, Canada based company registered on July 14, 2011, and 2458209 Ontario Inc. also an Ontario, Canada based company incorporated on March 17, 2015. Galileo Life Sciences SA, a company incorporated in Colombia on April 6, 2021.

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

References in this report refer to Modern Mobility Aid Inc. and its all four subsidiary companies, on a consolidated basis, unless otherwise indicated or the context otherwise requires.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

- As of now, the Company maintains an active status in Nevada after a revocation, followed by a reinstatement on November 19, 2023.

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

- The Company's BID and ASK privileges were downgraded to "Gray" listing as of November 15, 2023, due to the Company's is delinquent in its filings. However, the company has retained the services of an advisor to file with FINRA a 15c2-11 application and engage a market-maker on behalf of the company in order to initiate trading in the Company's shares.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

- Not applicable.

The address(es) of the issuer's principal executive office:

- The Company does not own, use, or lease any plant, properties, or other facilities. We are currently operating out of leased offices at 1968 S. Coast Hwy. Suite1094, Laguna Beach CA 92651.

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

- 79 Bramsteele Road,
Brampton, ONTARIO L6W 3K6

Has the Company's or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

If the Company's or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

- Not Applicable.

2. Security Information

The Issuer trades on the pink sheets maintained by OTC Markets Group, Inc.

The Transfer Agent:

Vstock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
(212) 828-8436
www.vstocktransfer.com

Is the Transfer Agent registered under the Exchange Act?² Yes: No:

² To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

The exact title and class of securities outstanding.

Trading symbol:	MDRM	
Exact title and class of securities outstanding:	Common Stock	
CUSIP:	607674108	
Par or stated value:	\$0.001	
Total shares authorized:	1,000,000,000	as of date: September 30, 2024
Total shares outstanding:	305,012,448	as of date: September 30, 2024
Total number of shareholders of record:	94	as of date: September 30, 2024

All additional class(es) of publicly traded securities (if any):

Trading symbol:	Not Applicable	
Exact title and class of securities outstanding:	Not Applicable	
CUSIP:	Not Applicable	
Par or stated value:	Not Applicable	
Total shares authorized:	Not Applicable	as of date: Not Applicable
Total shares outstanding:	Not Applicable	as of date: Not Applicable
Total number of shareholders of records:	Not Applicable	

Other classes of authorized or outstanding equity securities:

Trading symbol:	Not Applicable	
Exact title and class of securities outstanding:	Not Applicable	
CUSIP:	Not Applicable	
Par or stated value:	Not Applicable	
Total shares authorized:	Not Applicable	as of date: Not Applicable
Total shares outstanding:	Not Applicable	as of date: Not Applicable
Total number of shareholders of records:	Not Applicable	

Security Description

- **Common equity, dividend, voting and preemption rights.**

Common Stock

The Articles of Incorporation of the Issuer authorize the issuance of 1,000,000,000 shares of common stock, par value \$0.001 per share. On May 15, 2018, the Company filed an amendment to increase the number of shares that the Company is authorized to issue from 200,000,000 shares of common stock to 1,000,000,000 shares of common stock at \$0.001 par value per share.

Holders of common stock are entitled to one vote per share on all matters to be voted on by the stockholders. Holders of common stock are entitled to receive ratable such dividends, if any, as may be declared by the Board of Directors out of funds legally available thereof. In the event of a liquidation, dissolution, or winding up of the Company, the holders of common stocks are entitled to share rateably in all of our assets, which are legally available for distribution after payment of all debts and other liabilities and liquidation preference of any outstanding stock.

Holders of our common stock have no pre-emptive rights to purchase common stock. There are no conversion or redemption rights or sinking fund provisions with respect to the common stock. The outstanding shares of common stock are validly issued, fully paid and non-assessable.

- **Preferred stock, dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

Preferred Stock

The Articles of Incorporation of the Issuer authorize the issuance of 1,000,000 shares of preferred stock, par value \$0.001 per share. At the end of the quarter, 1,000,000 preferred stocks were issued and outstanding.

On January 12, 2015, the Company, by amending its articles of incorporation, authorized one million Series A preferred shares without designation. Resolution was made on January 12, 2015, and filed with the State of Nevada approving the designation of certain rights and privileges to such preferred shares. Included in those designations are conversion rights into common shares of the Company. For each Series "A" preferred share converted, the shareholder shall receive eight common shares of the Company and voting privileges equal to two hundred votes for each Series "A" share where preferred shares are entitled to vote.

On November 1, 2016, the Company issued 500,000 Series A-1 preferred shares at \$0.05 per share in full satisfaction of outstanding debt to one of the shareholders.

The Articles of Incorporation provide the Board with the right from time to time, to issue all or part of the shares of preferred stock remaining undesignated in one or more series, and to fix the number of shares of preferred stock and determine or alter for each series, the voting powers, full, limited, or none, and other designations, preferences, or relative, participating, optional or other special rights and such qualifications, limitations, or restrictions thereof.

- **Other material rights of common or preferred stockholders.**

Not applicable

- **Any material modifications to rights of holders of the company’s securities that have occurred over the reporting period covered by this report.**

Not applicable

3. Issuance History

A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years

No: Yes: (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance:</u> As at Oct 01, 2022, Common: <u>230,012,448</u> Preferred: <u>1,000,000</u>									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
January 10, 2024	New	75,000,000	Common	\$75,000	No	Razvi Family Trust - (Dr. Nayyar Razvi controlling 100% Rights)	Debt Conversion	Yes	N/A
Shares Outstanding on Date of This Report: <u>Ending Balance:</u> Date September 30, 2024, Common: <u>305,012,448</u> Preferred: <u>1,000,000</u>									

B. Debt Securities, Including Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer’s equity securities: No: Yes: (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)

4. Business, products and services.

A. Summarize the Company’s business operations (If the issuer does not have current operations, state “no operations”)

Description of Business

The Company currently focuses on Digital Health, Virtual Care, Cardiac Monitoring, Mental Health, Tele-Monitoring, and other emerging opportunities within the dynamic healthcare landscape, with a keen emphasis on the United States/Canadian, African and Latin American markets. The Company aims to create a unified platform for delivering Virtual Health Care services and home medical monitoring. Seeking to acquire controlling interests in value-added companies while preserving their autonomy and entrepreneurial essence, the Company plans to secure additional capital for these acquisitions, although there is a no guarantee that the funds will be secured, or the acquisitions will be done in case funds are available.

As part of its strategy, the Company intends to acquire, license, or invest in various global medical technology entities. It aims to construct a Telehealth platform that efficiently matches patients with appropriate professionals for their specific conditions and to integrate an e-commerce platform facilitating real-time doctor consultations and doctor-patient interactions. Furthermore, the Company is actively establishing an advisory board comprising medical and regulatory experts to drive support for engaging with medical practitioners and expanding outreach.

While management of the Company believes that the Company will be successful in its planned operating activities under its business plan and capital formation activities, there can be no assurance that it will be successful in implementation of its business plan or the formation of sufficient capital such that it will generate adequate revenues to earn a profit or sustain its operations.

B. Describe any subsidiaries, parents, or affiliated companies.

The Company has incorporated four wholly owned subsidiary companies: Modern Mobility Aid Inc., (name changed to Ayden Health Inc. on May 22, 2020), an Ontario, Canada, based company registered on September 09, 2009, and MDRM Group (Canada) Ltd. an Ontario, Canada based company registered on July 14, 2011, and 2458209 Ontario Inc. also an Ontario, Canada based company incorporated on March 17, 2015, and Galileo Life Sciences SA, a company incorporated in Colombia on April 6, 2021.

References in this report refer to Modern Mobility Aid Inc. and all its four subsidiary companies, on a consolidated basis, unless otherwise indicated or the context otherwise requires.

Contact information:

1968 S. Coast Hwy.
 Suite1094, Laguna Beach CA 92651
 Ph: 416 254 2581

C. Describe the issuers’ principal products or services.

The Company is currently concentrating on the Digital Health, Telehealth, Virtual Care, Cardiac Monitoring, Mental Health, Tele-Monitoring, and other emerging opportunities in rapidly changing healthcare environment with a special focus on Canadian, Latin America and US markets. The Company aims to build a common/shared platform through which it can

provide Virtual Health Care services and home medical monitoring.

5. Company's Facilities

The Company does not own, use, or lease any plant, properties, or other facilities. We are currently operating out of leased offices at 1968 S. Coast Hwy. Suite1094, Laguna Beach CA 92651. Management believes the current premises are sufficient for its needs at this time. Starting from September 01, 2021, the Company has acquired an office space on lease at 79 Bramsteele, Brampton, Ontario, Canada L6W 3K6.

6. Officers, Directors, and Control Persons

The subsequent table provides information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, the table also includes information regarding all individual(s) or entities controlling 5% or more of any class of the Company's securities.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Amar Bhatia	Owner of more than 5%	Toronto, Ontario	17,193,676	Common	5.63%	None
Tito DiMarco	CEO, Director & CFO	Toronto, Ontario	2,910,000 1,000,000	Common Preference	0.95%, 100%	None/ None
Dr. Nayyar Razvi	Owner of more than 5%	Toronto, Ontario	75,000,000	Common	24.58%	None

Director and Executive Officer Summary

The executive officers and directors of Modern Mobility Aid Inc., are:

Name & Address	Age	Position
Tito DiMarco Toronto, Ontario	75	Chief Executive Officer, Director and Chief Financial Officer
Dr. Zakiuddin Ahmed United Arab Emirates	56	President

Directors are elected to serve until the next annual meeting of stockholders and until their successors have been elected and qualified. Officers are appointed to serve until the meeting of the Board of Directors following the next annual meeting of stockholders and until their successors have been elected and qualified.

Our executive officers expect to devote such time as they deem necessary to managing the affairs of the Company.

No executive officer or director of the corporation has been the subject of any order, judgment, or decree of any court of competent jurisdiction, or any regulatory agency permanently or temporarily enjoining, barring, suspending or otherwise limiting him or her from acting as an investment advisor, underwriter, broker or dealer in the securities industry, or as an affiliated person, director or employee of an investment company, bank, savings and loan association, or insurance company or from engaging in or continuing any conduct or practice in connection with any such activity or in connection with the purchase or sale of any securities.

No executive officer or director of the corporation has been convicted in any criminal proceeding (excluding traffic violations) or is the subject of a criminal proceeding which is currently pending.

Tito DiMarco. Mr. DiMarco has over forty years of experience as a distributor. From approximately 2001 to current date, Mr. DiMarco has been the president of Osvaldo Inc., a manufacturing and distribution company of organic juices and

mineral water. From approximately 2002 to the current date, Mr. DiMarco has also been engaged with Maitech Associates, Inc., which exports and imports medical equipment and parts, including parts for the oil and gas industry. Mr. DiMarco also served in the Canadian Army from 1969 to 1971.

Dr. Zakiuddin Ahmed: Dr. Ahmed has been appointed as President of the Company. Dr. Ahmed is a distinguished visionary healthcare entrepreneur, and physician advocate, and brings a wealth of expertise to the Company and will play a vital role in shaping the future of healthcare through technology.

Dr. Ahmed, an internationally recognized speaker, is renowned for his work in creating partnerships and collaborations, and developing innovative, sustainable solutions in healthcare, all with a patient-centric focus. His areas of specialization include eHealth, mHealth, Telemedicine, Digital Health, Patient Safety, Healthcare Quality, Medical Ethics, Health Research, Healthcare Leadership, and Physician Entrepreneurship. Since 1998, Dr. Ahmed has played a significant role in pioneering Telemedicine globally since 1998, making him a global expert in digital health.

7. Legal and Disciplinary History

A. Please identify whether any of the persons listed above in Section 6 have, in the past 10 years, been the subject of:

1. an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);
 - Not Applicable.
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities.
 - Not Applicable.
3. A finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated.
 - Not Applicable.
4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or
 - Not Applicable.
5. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.
 - Not Applicable.
6. A U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.
 - Not Applicable.

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a

description of the factual basis alleged to underlie the proceeding, and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

- Not Applicable.

8. Third Party Providers.

Securities Counsel

Morgan E. Petitti

118 W. Streetsboro Rd
Suite 317
Hudson, Ohio 44236,
USA.

Accounting Firm

OLAYINKA OYEBOLA & CO.

Chartered Accountants

10333 Harwin Dr. Suit #677,
Houston TX 77036,
USA

Investor Relations Consultant

- Not applicable

All other means of Investor Communication:

- Not applicable

Other Service Providers

- Not Applicable

9. Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: **Syed Tariq Mahmood**
Title: External Accountant
Relationship to Issuer: Independent Contractor

B. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

C. The following financial statements were prepared by (name of individual):

Name: **Syed Tariq Mahmood**
Title: External Accountant
Relationship to Issuer: Independent Contractor

Describe the qualifications of the person or persons who prepared the financial statements:⁵ Chartered Accountant

⁵ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

The financial statements of the Issuer as and for the Quarter Ended September 30, 2024, are incorporated herein as appendix 'A' for reference.

10. ISSUER CERTIFICATIONS.

PRINCIPAL EXECUTIVE OFFICER'S CERTIFICATION

I, Tito DiMarco, the Chief Executive Officer of Modern Mobility Aid Inc. hereby certify that:

1. I have reviewed this Quarterly Disclosure Statement of Modern Mobility Aid, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: November 13, 2024

/s/ Tito DiMarco

By: **Tito DiMarco**
Title: Chief Executive Officer and
Chief Financial Officer

PRINCIPAL FINANCIAL OFFICER'S CERTIFICATION

I, Tito DiMarco, the Chief Financial Officer of Modern Mobility Aid Inc. hereby certify that:

1. I have reviewed this Quarterly Disclosure Statement of Modern Mobility Aid Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: November 13, 2024

/s/ Tito DiMarco

By: **Tito DiMarco**
Title: Chief Financial Officer

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
CONSOLIDATED FINANCIAL STATEMENTS
FOR THE QUARTER ENDED
SEPTEMBER 30, 2024

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
CONSOLIDATED BALANCE SHEETS
AS AT SEPTEMBER 30

	Notes	2024	2023
<u>ASSETS</u>			
Current Assets:			
Cash		\$ 170	\$ 187
Short term advances and deposits	4	136,067	39,972
Loans receivables		78,894	78,710
Other current receivables		23,411	17,014
Total Current Assets		<u>\$ 238,372</u>	<u>135,883</u>
Total Assets		<u><u>\$ 238,542</u></u>	<u><u>\$ 135,883</u></u>
<u>LIABILITIES AND STOCKHOLDERS' DEFICIT</u>			
Current Liabilities:			
Accounts payable and accrued liabilities		\$ 624,008	\$ 467,184
Loan from shareholders	5	245,996	161,680
Other loans payable- related parties	6	147,461	101,677
Total Current Liabilities		<u>\$ 1,017,465</u>	<u>\$ 730,541</u>
Long Term Liabilities:			
Long term loan	7	\$ 29,279	\$ 29,138
Total Liabilities		<u>\$ 1,046,744</u>	<u>\$ 759,679</u>
Stockholders' Deficit:			
Preferred stock, par value \$0.001 per share, 1,000,000 shares authorized; shares issued and outstanding 1,000,000 and 1,000,000, respectively		\$ 1,000	\$ 1,000
Common stock, par value \$0.001 per share, 1,000,000,000* shares authorized; 305,012,448 (2023: 230,012,448) issued and outstanding, respectively		305,012	230,012
Additional paid in capital		4,186,736	4,186,736
Accumulated deficit		(5,300,950)	(5,041,544)
Total Stockholders' Deficit		<u>(808,202)</u>	<u>(623,796)</u>
Total Liabilities and Stockholders' Deficit		<u><u>\$ 238,542</u></u>	<u><u>\$ 135,883</u></u>

* as amended on May 14, 2018.

The accompanying notes are an integral part of these consolidated financial statements.

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE QUARTER ENDED SEPTEMBER 30

	<u>Notes</u>	<u>2024</u>	<u>2023</u>
Revenues, net	8	\$ -	\$ -
Operating Expenses:			
Consulting fees, related parties	9 (a)	22,642	22,074
Consulting fees, third parties	(b)	2,682	5,801
Legal and professional fees		2,033	1,950
Office and general expenses		2,253	1,386
Total operating expenses		<u>\$ 29,610</u>	<u>\$ 31,211</u>
(Loss) from Operations		<u>\$ (29,610)</u>	<u>\$ (31,211)</u>
Other Income/(Expense)	10	(202)	(77)
Profit/(Loss) Before Taxes		<u>\$ (29,812)</u>	<u>\$ (31,288)</u>
Provision for Taxes		-	-
Net Profit/(Loss) for the quarter		<u>\$ (29,812)</u>	<u>\$ (31,288)</u>
Loss Per Common Share:			
Basic and Diluted:		\$(0.00)*	\$ (0.00)*
Weighted Average Number of Common Shares			
Outstanding:			
Basic and Diluted		<u>305,012,448</u>	<u>230,012,448</u>

* denotes a loss of less than \$(0.01) per share

The accompanying notes are an integral part of these consolidated financial statements.

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
CONSOLIDATED STATEMENT OF MOVEMENT IN STOCKHOLDERS' DEFICIT

Description	Preferred Shares	Amount	Common Shares	Amount	Additional Paid in Capital	Acc. Deficit	TOTAL
Balance - Oct 01, 2023	1,000,000	\$ 1,000	230,012,448	\$ 230,012	\$ 4,186,736	\$ (5,010,257)	\$ (592,509)
Issuance of common shares during the year	-	-	75,000,000	\$75,000	-	-	\$75,000
Net (loss) for the year	-	-	-	-	-	\$ (260,881)	\$ (260,881)
Balance – June 30, 2024	1,000,000	\$ 1,000	305,012,448	\$ 305,012	\$ 4,186,736	\$ (5,271,138)	\$ (778,390)
Net (loss) for the quarter	-	-	-	-	-	\$ (29,812)	\$ (29,812)
Balance – September 30, 2024	1,000,000	\$ 1,000	305,012,448	\$ 305,012	\$ 4,186,736	\$ (5,300,950)	\$ (808,202)

The accompanying notes are an integral part of these consolidated financial statements.

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE QUARTER ENDED SEPTEMBER 30

	2024	2023
OPERATING ACTIVITIES:		
Net (loss) for the quarter	\$ (29,812)	\$ (31,288)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:		
Un-realized currency translation (gains)/losses	-	(560)
Changes in Current Assets and Liabilities		
Advances, loans, and other receivables	-	4,946
Consulting fee payable-related parties	22,642	22,074
Accounts payable and accrued liabilities	(893)	2,520
Net Changes in Current Assets and Liabilities	\$ 21,749	\$ 29,540
Net Cash (Used in) Operating Activities	\$ (8,063)	\$ (2,308)
FINANCING ACTIVITIES:		
Loans from shareholders	8,094	(426)
Other loans payable- related parties	-	2,575
Net Cash Provided by Financing Activities	\$ 8,094	\$ 2,149
Net Increase (decrease) in Cash	\$ 31	\$ (159)
Cash - Beginning of Period	\$ 139	\$ 346
Cash - End of Period	\$ 170	\$ (187)
Supplemental Disclosure of Cash Flow Information:		
Cash paid/converted during the period for:		
Interest	\$ 178	\$ 274
Income taxes	\$ -	\$ -

The accompanying notes are an integral part of these consolidated financial statements.

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE QUARTER ENDED SEPTEMBER 30, 2024, AND 2023

1. DESCRIPTION OF BUSINESS

Modern Mobility Aids, Inc. (the “Company”) was incorporated under the laws of the State of Nevada on December 19, 2007, under the name Glider Inc. with a business plan to sell and distribute products for mobility challenged individuals. The Company changed its name to Modern Mobility Aids, Inc. on April 22, 2010, and to Galileo Life Sciences, Inc. on December 12, 2014. On October 3, 2017, the Company changed its name back to Modern Mobility Aids, Inc. The Company again has changed its name to Galileo Life Sciences, Inc. on March 12, 2021. The Company again changed its name to Modern Mobility Aids Inc. on November 19, 2023.

Since May 2011, The Company is focused on the emerging opportunities in Cannabis space i.e., both medical and recreational, with a special focus on the Canadian market. Earlier the Company was distributing mobility aids products for physically challenged individuals which generated limited revenues.

The Company currently focuses on Digital Health, Virtual Care, Cardiac Monitoring, Mental Health, Tele-Monitoring, and other emerging opportunities within the dynamic healthcare landscape, with a keen emphasis on the United States/Canadian, African and Latin American markets. The Company aims to create a unified platform for delivering Virtual Health Care services and home medical monitoring. Seeking to acquire controlling interests in value-added companies while preserving their autonomy and entrepreneurial essence, the Company plans to secure additional capital for these acquisitions, although there is a no guarantee that the funds will be secured, or the acquisitions will be done in case funds are available.

As part of its strategy, the Company intends to acquire, license, or invest in various global medical technology entities. It aims to construct a Telehealth platform that efficiently matches patients with appropriate professionals for their specific conditions and to integrate an e-commerce platform facilitating real-time doctor consultations and doctor-patient interactions. Furthermore, the Company is actively establishing an advisory board comprising medical and regulatory experts to drive support for engaging with medical practitioners and expanding outreach.

2. GOING CONCERN

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United State of America, which contemplate continuation of the Company as a going concern. The Company has not established a source of revenue sufficient to cover its operating costs, and as such, has incurred an operating loss on an ongoing basis. Further, as of September 30, 2024, and 2023, the Company had a working capital deficit of \$778,923 and \$594,658 respectively. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern.

The Company must raise additional funds to initiate or acquire a business and to fund our continued operations. We may not be successful in our efforts to raise additional funds or achieve profitable operations. Even if we are able to raise additional funds through the sale of our securities or through the issuance of debt securities, or loans from our shareholders or financial institutions, our cash needs could be greater than anticipated in which case we could be forced to raise additional capital.

At present, we have no commitments for any additional financing, and there can be no assurance that, if needed, additional capital will be available to us on commercially acceptable terms or at all. These conditions raise substantial doubt as to our ability to continue as a going concern, which may make it more difficult for us to raise additional capital when needed. If we cannot get the needed capital, we may not be able to become profitable and may have to curtail or cease our operations.

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE QUARTER ENDED SEPTEMBER 30, 2024, AND 2023

3. SIGNIFICANT ACCOUNTING POLICIES

Basis of Preparation

The accompanying audited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP")

Development Stage Company

The Company is in the development stage as defined under the then current Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 915-205 "Development-Stage Entities," and among the additional disclosures required as a development stage company are that our financial statements were identified as those of a development stage company, and that the statements of operations, stockholders' deficit and cash flows disclosed activity since the date of our inception (December 19, 2007) as a development stage company. Effective June 10, 2014, FASB changed its regulations with respect to Development Stage Entities and these additional disclosures are no longer required for annual reporting periods beginning after December 15, 2014, with the option for entities to early adopt these new provisions. The Company has elected to early adopt these provisions and consequently these additional disclosures have not been included in these financial statements.

Principles of Consolidation

The Company's consolidated financial statements for the quarter ended September 30, 2024, include the accounts of its wholly owned subsidiaries Modern Mobility Aid Inc., (name changed to Ayden Health Inc. on May 22, 2020), an Ontario, Canada, based company registered on September 09, 2009, and MDRM Group (Canada) Ltd. an Ontario, Canada based company registered on July 14, 2011, and 2458209 Ontario Inc. also an Ontario, Canada based company incorporated on March 17, 2015. Galileo Life Sciences SA, a company incorporated in Colombia on April 6, 2021. All significant intercompany balances and transactions have been eliminated for consolidation purposes.

Cash and Cash Equivalents

For purposes of reporting within the statements of cash flows, the Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents.

Revenue Recognition

The Company is in the development stage and has realized minimal revenues from operations. The Company recognizes revenues when the sale and/or distribution of products is complete, risk of loss and title to the products have transferred to the customer, there is persuasive evidence of an agreement, acceptance has been approved by its customer, the fee is fixed or determinable based on the completion of stated terms and conditions, and collection of any related receivable is probable. Net revenues are comprised of gross revenues less expected returns, trade discounts, and customer allowances that include costs associated with off-invoice markdowns and other price reductions, as well as trade promotions and coupons. These incentive costs are recognized at the later date on which the Company recognizes the related revenue or the date on which the Company offers the incentive.

Loss per Common Share

Basic loss per share is computed by dividing the net loss attributable to the common stockholders by the weighted average number of shares of common stock outstanding during the periods. Diluted loss per share is computed similar to basic loss

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE QUARTER ENDED SEPTEMBER 30, 2024, AND 2023

3. SIGNIFICANT ACCOUNTING POLICIES - *continued*

per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments issued or outstanding for the quarter ended September 30, 2024, and 2023.

Income Taxes

The Company accounts for income taxes pursuant to SFAS No. 109, “*Accounting for Income Taxes*” (“SFAS No. 109”). Under SFAS No. 109, now encompassed under ASC 740, deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

The Company maintains a valuation allowance with respect to deferred tax assets. Modern Mobility Aid Inc. establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration the Company’s financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carryforward period under the Federal tax laws.

Changes in circumstances, such as the Company generating taxable income, could cause a change in judgment as to whether the related deferred tax asset could be realized. Any change in the valuation allowance will be included in income in the year of the change in estimate.

Fair Value of Financial Instruments

The Company estimates the fair value of financial instruments using the available market information and valuation methods. Considerable judgment is required in estimating fair value. Accordingly, the estimates of fair value may not be indicative of the amounts Modern Mobility Aids, Inc. could realize in a current market exchange. As of September 30, 2024, the carrying value of the Company’s financial instruments approximated fair value due to the short-term nature and maturity of these instruments.

Deferred Offering Costs

The Company defers as other assets the direct incremental costs of raising capital until such a time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated.

Impairment of Long-lived Assets

Capital assets are reviewed for impairment in accordance with SFAS No. 144, “*Accounting for the Impairment of Disposal of Long-lived Assets*,” which was adopted effective January 1, 2002. Under SFAS No. 144, now encompassed under ASC 350, these assets are tested for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the quarter ended September 30, 2024, and 2023, no events or circumstances occurred for which an evaluation of the recoverability of long-lived assets was required.

Advertising and Promotion

The Company expenses all advertising and promotion costs as incurred. The Company incurred “Nil”, as advertising and promotion costs during the quarter ended September 30, 2024. Also, there was no advertisement cost incurred during the same quarter in 2023.

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE QUARTER ENDED SEPTEMBER 30, 2024, AND 2023

3. SIGNIFICANT ACCOUNTING POLICIES - *continued*

Stock-based Compensation

The Company accounts for employee and non-employee stock awards under ASC 718, whereby equity instruments issued to employees for services are recorded based on the fair value of the instrument issued and those issued to non-employees are recorded based on the fair value of the consideration received or the fair value of the equity instrument, whichever is more reliably measurable.

Foreign Currency Transactions

Foreign currency transaction gains and losses are recorded in the statements of operation as a component of other income/ (expense).

Use of Estimates and Assumptions

The accompanying financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America. Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements for a period necessarily involves the use of estimates which have been made using careful judgment. Actual results may vary from these estimates.

Reclassifications

Certain amounts previously presented for prior periods have been reclassified. The reclassifications had no effect on net loss, total assets, or total shareholders' deficit.

Recently Adopted Accounting Pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial condition or the results of its operations other than in respect of the early adoption of the new regulations relating to Development Stage Entities as discussed above.

4. SHORT TERM ADVANCES AND DEPOSITS

The Company engaged software developing companies to build Telehealth platform to provide Virtual Health Care services and medical monitoring. The Company has made advance payments to acquire medical devices to provide Telehealth services to its clients.

On March 1, 2024, the Company has entered an "Memorandum of Understanding" (the "Agreement") with **MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES** (hereinafter referred to as **MUHAS**) in Dar-es-Salaam, TANZANIA. MUHAS has been mandated by the Ministry of Health in Tanzania. The overall objective of the MOU is to foster research, innovation, capacity building, collaboration, and partnerships in promoting digital transformation and supporting the Government's efforts to promote digital health transformation, knowledge management and dissemination. MUHAS, in collaboration with the Government and partners, organizes the different digital health initiatives include the MUHAS Annual Digital Health and Innovation Week initiative (MADWI), including the Digital Health and Innovation Forum and Exhibition, training, and partnership and network meetings.

The Company and MUHAS shall promote cooperation to achieve the following:

- a) Collaboration in any field of common interest related to digital health.
- b) Capacity building on digital health-related programmers, including digital health leadership and governance, data analytics, among others.

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE QUARTER ENDED SEPTEMBER 30, 2024, AND 2023

- c) Fields related to cooperation in delivering digital health-related research, consultancy, innovation, emerging technologies, and development matters.
- d) Improving the quality of capacity-strengthening interventions on digital health-related issues that might link to usage /improvement of digital health.
- e) Joint knowledge management and dissemination, including seminars, conferences and public lectures, publications, exchange of publications, academic materials, and other information.
- f) All Parties agree upon other projects or programs for mutual benefit.

Subsequent to this development, the Company identified the need to develop an eHealth educational platform for them. Consequently, a prominent eHealth technology expert was contracted by the Company during the year, who known for the pioneering the world's first telemedicine technician program at Ceridian College in Toronto, ONTARIO, CANADA and for his significant contributions to shaping telemedicine platforms. He has remotely assisted over 25,000 patients and leads MD-Matrix, a prominent healthcare technology firm in Toronto, ONTARIO, CANADA. In pursuant to the agreement, the Company shall receive a Telehealth Educational course platform tailored for the use in universities, colleges and online physician training programs focused on eHealth. The total cost of the service is \$75,000, which was paid in advance by the issuance of the Company's 75,000,000 common stock at the market price of \$0.001 on the date of the issuance of the shares.

5. LOAN FROM SHAREHOLDERS

In support of the Company's efforts and cash requirements, it may rely on advances from shareholders until such a time that the Company can support its operations or attain adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances are considered temporary in nature and have not been formalized by a promissory note.

As of September 30, 2024, the Company owed a balance of \$245,996 to shareholders. The loans are payable on demand, unsecured and bears no interest.

6. OTHER LOANS PAYABLE-RELATED PARTIES

In addition to the loans from shareholders, the Company also relies on financial support from third parties to meet its operational requirements. This reliance may continue until such a time that the Company can support its operations or attain adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by third parties. Amounts represent advances or amounts paid in satisfaction of liabilities.

As of September 30, 2024, there was a balance of \$147,461 for other loans payable arising from short term advances to the Company to meet operational needs. The amount is unsecured, with no formal agreed upon rate of interest and is payable on demand.

7. LONG TERM LOANS

The Company has obtained a VISA Credit Line from a Canadian financial institution for an amount of \$31,674 (CAD\$40,000) under the Canada Emergency Business Account (CEBA) loan facility that was one of the Government of Canada financial relief financial measures to support Canadian businesses that have been adversely affected by COVID-19 pandemic. The loan is unsecured and interest free, if paid until December 31, 2023 ("Initial Term Date"). Additionally, if the repayment is made at least 75% of the Loan amount on or prior to the Initial Term Date, the remaining balance of the Loan amount as of the Initial Term Date, will be forgiven by the financial institution, provided that an Event of Default has not occurred. However, since the Company has not paid the loan, the financial institution will charge interest at the rate of 5% per annum. The forgiveness repayment date of January 18, 2024, for eligible CEBA Loan Holders in good standing has now passed. Eligible CEBA Loans that remain outstanding are now non-amortizing term loans with full principal repayment due on December 31, 2026.

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE QUARTER ENDED SEPTEMBER 30, 2024, AND 2023

As of September 30, 2024, the Company owed a balance of \$29,279. No net exchange gain recorded during the current quarter ended September 30, 2024.

8. REVENUES

The Company's source of revenue is providing Telehealth, Virtual Care, Cardiac Monitoring, Mental Health, Tele-Monitoring to individuals who require these services. In this respect, the Company has entered into a revenue sharing agreement with an Ontario based Medical professional Corporation (the "Corporation") to provide administrative support services to physicians at their clinics located in multiple locations in the Greater Toronto Area. The Corporation provides virtual medical services at the clinics from Monday to Saturday. Pursuant to the terms of the agreement, the revenue will be shared in the proportion of 70:30 ratio, where the Company will get thirty (30) percent of the gross revenues plus applicable taxes, generated by the Corporation. The clinics are located in various pharmacies in Ontario. Under the terms, the Company is not responsible to pay for the rent, utilities and other related expenses for the space provided by pharmacies.

9. CONSULTING FEES

a.) RELATED PARTIES

The Company recognizes that it is essential to attract and retain officers and directors who are qualified, capable, and willing to serve the Company. Each one of them performs a valuable service for the Company and is entitled to and should be fairly compensated for such services and the duties and responsibilities imposed by the Company, its bylaws, federal and state statutes, and various regulatory bodies.

In recognition of the valuable services performed by its officers and executives, the Board of Directors approved payment of consulting services amount to its executives. On January 14, 2021, the Company also entered into employment agreements with two of its directors to be renewed on an annual basis. Pursuant to the terms of the agreements, one executive received a 10,000,000 (Ten million) common shares of the Company, as a signing bonus, from the Company and the other executive received a 10,000,000 (Ten million) common shares of the Company against his past services to the Company. The Company issued a total of 20,000,000 (twenty million) common shares of the Company on the date of the execution of the agreements. One of the executives resigned from his position on December 11, 2023.

The total amount accrued as consulting fees to the related parties for the quarter ended September 30, 2024, was \$22,642.

b.) THIRD PARTIES

Considering the valuable services performed by third parties, the Company has made payments as consulting services to third parties during the quarter. The total amount accrued for consulting fee related to third parties for the quarter ended September 30, 2024, was \$2,682.

10. OTHER INCOME/(EXPENSES)

The other income/(expenses) contains a loss of foreign exchange of \$24 for the quarter ended September 30, 2024.

11. INCOME TAXES

The provision (benefit) for income taxes for the quarter ended September 30, 2024, and 2023, were as follows (assuming a 15 percent effective tax rate):

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE QUARTER ENDED SEPTEMBER 30, 2024, AND 2023

	Quarter ended September 30,	
	2024	2023
Current Tax Provision:		
Federal		
Taxable (loss)/Profit	\$ (4,472)	\$ (4,693)
Valuation allowance	4,472	4,693
Total current tax provision	\$ -	\$ -
Cumulative Tax Provision:		
Federal		
Loss carryforwards	\$ 795,143	\$ 756,232
Change in valuation allowance	\$ (795,143)	\$ (756,232)
Total deferred tax provision	\$ -	\$ -

The Company had carried forward tax losses as of September 30, 2024, and 2023 as follows:

	Quarter ended September 30,	
	2024	2023
Loss carryforwards	\$ 5,300,950	\$ 5,041,544
Less - Valuation allowance	\$ (5,300,950)	\$ (5,041,544)
Total net deferred tax assets	\$ -	\$ -

As of September 30, 2024, the Company had approximately \$5,300,950 in tax loss carry forwards that can be utilized in future periods to reduce taxable income and begin to expire in the year 2028.

The Company provided a valuation allowance equal to the deferred income tax assets for the quarter ended September 30, 2024, and 2023 because it is not presently known whether future taxable income will be sufficient to utilize the loss carry forwards.

12. SHAREHOLDERS' DEFICIT

Preferred Stock

The Articles of Incorporation of the Issuer authorize the issuance of 1,000,000 shares of preferred stock, par value \$0.001 per share. No preferred stocks were issued during the quarter ended September 30, 2024, and 2023. **1,000,000** preferred stocks were issued and outstanding at the end of the quarter September 30, 2024, and 2023.

On January 12, 2015, the Company, by amending its articles of incorporation, authorized one million Series A preferred shares without designation. Resolution was made on January 12, 2015, and filed with the State of Nevada approving the designation of certain rights and privileges to such preferred shares. Included in those designations are conversion rights into common shares of the Company. For each Series "A" preferred share converted, the shareholder shall receive eight common shares of the Company and voting privileges equal to two hundred votes for each Series "A" share where preferred shares are entitled to vote.

On November 1, 2016, the Company issued 500,000 Series A-1 preferred shares at \$0.05 per share in full satisfaction of outstanding debt to one of the shareholders.

The Articles of Incorporation provide the Board with the right from time to time, to issue all or part of the shares of preferred stock remaining undesignated in one or more series, and to fix the number of shares of preferred stock and determine or

MODERN MOBILITY AIDS, INC.
(FORMERLY GALILEO LIFE SCIENCES, INC.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE QUARTER ENDED SEPTEMBER 30, 2024, AND 2023

alter for each series, the voting powers, full, limited, or none, and other designations, preferences, or relative, participating, optional or other special rights and such qualifications, limitations, or restrictions thereof.

Common Stock

The Articles of Incorporation of the Issuer authorize the issuance of 1,000,000,000 shares of common stock, par value \$0.001 per share. On May 15, 2018, the Company filed an amendment to increase the number of shares that the Company is authorized to issue from 200,000,000 shares of common stock to 1,000,000,000 shares of common stock at \$0.001 par value per share while series "A" preferred shares remain at 1,000,000 at \$0.001 par value per share.

Holders of common stock are entitled to one vote per share on all matters to be voted on by the stockholders. Holders of common stock are entitled to receive ratable such dividends, if any, as may be declared by the Board of Directors out of funds legally available thereof. In the event of a liquidation, dissolution, or winding up of the Company, the holders of common stocks are entitled to share rateably in all of our assets which are legally available for distribution after payment of all debts and other liabilities and liquidation preference of any outstanding stock.

Holders of our common stock have no pre-emptive rights to purchase common stock. There are no conversion or redemption rights or sinking fund provisions with respect to the common stock. The outstanding shares of common stock are validly issued, fully paid and non-assessable.

As of September 30, 2024, there were **305,012,448** common shares issued and outstanding. As of the balance sheet date, the Company had not granted any stock options under share-based compensation transactions.

13. SUBSEQUENT EVENTS

In accordance with ASC 855, Subsequent Events, the Company has evaluated events that occurred subsequent to the balance sheet date through the date of the issuance of these financial statements. The Company determined that there was no material subsequent event to be disclosed.

Signatures

In accordance with Section 13 or 15(d) of the Securities Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MODERN MOBILITY AIDS, INC.

Date: November 13, 2024

By: /s/ Tito DiMarco
Tito DiMarco
Chief Executive Officer, Director, and CFO

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons on November 13, 2024, in the capacities and on the dates indicated:

Signature _____

Title _____

/s/ Tito DiMarco
Tito DiMarco

Chief Executive Officer, Director, and CFO